Eli Lilly & Co. Sees Unusually Large Options Volume (LLY)
Eli Lilly & Co. (NYSE:LLY) saw some unusual options trading activity on Thursday. Traders acquired 15,325 call options on the stock, StockRatingsNetwork.com reports. This is an increase of 102% compared to the typical volume of 7,598 call options.
A number of analysts have recently weighed in on LLY shares. Analysts at Goldman Sachs Group Inc. cut their price target on shares of Eli Lilly & Co. (NYSE:LLY) to $54.00 in a research note to investors on Thursday. Separately, analysts at Sanford C. Bernstein reiterated a “buy” rating on shares of Eli Lilly & Co. (NYSE:LLY) in a research note to investors on Tuesday. They now have a $61.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Eli Lilly & Co. (NYSE:LLY) from $59.00 to $61.00 in a research note to investors on Tuesday. They now have a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $57.33.
Eli Lilly & Co. (NYSE:LLY) opened at 51.04 on Friday. Eli Lilly & Co. has a 52-week low of $44.88 and a 52-week high of $58.40. The stock has a 50-day moving average of $52.8 and a 200-day moving average of $53.62. The company has a market cap of $55.133 billion and a P/E ratio of 11.46.
Eli Lilly & Co. (NYSE:LLY) last issued its quarterly earnings data on Wednesday, July 24th. The company reported $1.16 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.01 by $0.15. The company had revenue of $5.93 billion for the quarter, compared to the consensus estimate of $5.82 billion. During the same quarter in the prior year, the company posted $0.83 earnings per share. The company’s quarterly revenue was up 5.9% on a year-over-year basis. On average, analysts predict that Eli Lilly & Co. will post $4.14 earnings per share for the current fiscal year.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.